Michael Heuser

28.4k total citations · 2 hit papers
250 papers, 6.7k citations indexed

About

Michael Heuser is a scholar working on Hematology, Molecular Biology and Genetics. According to data from OpenAlex, Michael Heuser has authored 250 papers receiving a total of 6.7k indexed citations (citations by other indexed papers that have themselves been cited), including 184 papers in Hematology, 132 papers in Molecular Biology and 72 papers in Genetics. Recurrent topics in Michael Heuser's work include Acute Myeloid Leukemia Research (175 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (43 papers) and Chronic Myeloid Leukemia Treatments (33 papers). Michael Heuser is often cited by papers focused on Acute Myeloid Leukemia Research (175 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (43 papers) and Chronic Myeloid Leukemia Treatments (33 papers). Michael Heuser collaborates with scholars based in Germany, United States and Canada. Michael Heuser's co-authors include Arnold Ganser, Felicitas Thol, Brigitte Schlegelberger, Gudrun Göhring, Jürgen Krauter, Walter Fiedler, Frédérik Damm, Katharina Wagner, Richard F. Schlenk and Oliver G. Ottmann and has published in prestigious journals such as New England Journal of Medicine, Nature Genetics and Journal of Clinical Oncology.

In The Last Decade

Michael Heuser

238 papers receiving 6.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome

2018 354 citations Florian H. Heidel, Walter Fiedler et al. Leukemia profile →
Ivosidenib and Azacitidine in IDH1 -Mutated Acute Myeloid Leukemia

2022 295 citations Pau Montesinos, Christian Récher et al. profile →

Peers

Countries citing papers authored by Michael Heuser

Since Specialization

Citations

This map shows the geographic impact of Michael Heuser's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Heuser with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Heuser more than expected).

Fields of papers citing papers by Michael Heuser

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Heuser. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Heuser. The network helps show where Michael Heuser may publish in the future.

Co-authorship network of co-authors of Michael Heuser

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Heuser. A scholar is included among the top collaborators of Michael Heuser based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Heuser. Michael Heuser is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Genetic and epigenetic alterations at secondary resistance after continued decitabine-based treatment of acute myeloid leukemia in the randomized phase II DECIDER trial 2025 ·Leukemia ·(unknown), (unknown), Geoffroy Andrieux, (unknown), Gabriele Greve, (unknown), (unknown), (unknown), (unknown), Felicitas Thol, Michael Heuser, Gesine Bug, Martina Crysandt, Andreas Neubauer, Justus Duyster, Hartmut Döhner, Melanie Boerries, Michael Lübbert, Heiko Becker	0
2	XPO1-dependency of DEK::NUP214 leukemia 2025 ·Leukemia ·(unknown), Arnold Kloos, (unknown), (unknown), Robert Geffers, (unknown), (unknown), Kerstin Görlich, (unknown), Halyna R. Shcherbata, Michaela Scherr, Konstanze Döhner, Razif Gabdoulline, Michael Heuser	0
3	Cell‐free DNA for detection and monitoring of extramedullary AML relapse 2025 ·HemaSphere ·(unknown), (unknown), Stephan Bartels, Elisa Schipper, (unknown), (unknown), (unknown), Razif Gabdoulline, (unknown), Elke Dammann, Hans Kreipe, Ulrich Lehmann, Anke K. Bergmann, Nataliya Di Donato, Michael Stadler, Matthias Eder, Arnold Ganser, Florian H. Heidel, Felicitas Thol, Michael Heuser	2
4	Prognostic Impact of Subclinical FLT3-ITD Microclones in Patients with Acute Myeloid Leukemia 2024 ·Blood ·(unknown), Razif Gabdoulline, Rabia Shahswar, Arnold Kloos, Letizia Venturini, (unknown), (unknown), Victoria Panagiota, Michael Stadler, Matthias Eder, Gernot Beutel, Elke Dammann, P Poll, Anke K. Bergmann, Nataliya Di Donato, Florian H. Heidel, Felicitas Thol, Michael Heuser	1
5	Dose-Reduced FLA-IDA in Combination with Venetoclax Is an Effective and Safe Salvage Therapy in Relapsed and Refractory Acute Myeloid Leukemia (R/R AML) 2024 ·Cancers ·(unknown), (unknown), (unknown), Michael Heuser, Felicitas Thol, Francis Ayuk, Christine Wolschke, Evgeny Klyuchnikov, Carsten Bokemeyer, Walter Fiedler, (unknown)	0
6	In vivo kinetics of early, non-random methylome and transcriptome changes induced by DNA-hypomethylating treatment in primary AML blasts 2023 ·Leukemia ·Gabriele Greve, Geoffroy Andrieux, Pascal Schlosser, Nadja Blagitko‐Dorfs, (unknown), (unknown), Dietmar Pfeifer, (unknown), Andreas Neubauer, Jürgen Krauter, Michael Heuser, Helmut R. Salih, Konstanze Döhner, Hartmut Döhner, Björn Hackanson, Melanie Boerries, Michael Lübbert	2
7	Non-viral TRAC-knocked-in CD19KICAR-T and gp350KICAR-T cells tested against Burkitt lymphomas with type 1 or 2 EBV infection: In vivo cellular dynamics and potency 2023 ·Frontiers in Immunology ·(unknown), (unknown), Milita Darguzyte, (unknown), Phuong‐Hien Nguyen, Dimitrios L. Wagner, (unknown), (unknown), Michael Heuser, (unknown), Andreas Schneider, (unknown), Steven R. Talbot, André Bleich, Constança Figueiredo, Martin Bornhäuser, Renata Stripecke	12
8	Measurable residual disease monitoring in patients with acute myeloid leukemia treated with lower‐intensity therapy: Roadmap from an ELN‐DAVID expert panel 2023 ·American Journal of Hematology ·Farhad Ravandi, Jacqueline Cloos, Francesco Buccisano, Richard Dillon, Konstanze Döhner, Sylvie Freeman, Christopher S. Hourigan, G. J. Ossenkoppele, Gail J. Roboz, Marion Subklewe, Christian Thiede, (unknown), Peter J.M. Valk, Adriano Venditti, Andrew H. Wei, Roland B. Walter, Michael Heuser	10
9	Impact of TP53 on outcome of patients with myelofibrosis undergoing hematopoietic stem cell transplantation 2023 ·Blood ·Nico Gagelmann, Anita Badbaran, Rachel B. Salit, Thomas Schroeder, Carmelo Gurnari, Simona Pagliuca, Victoria Panagiota, Christina Rautenberg, Bruno Cassinat, Felicitas Thol, Christine Wolschke, Marie Robin, Michael Heuser, Marie‐Thérèse Rubio, Jaroslaw P. Maciejewski, Hans Christian Reinhardt, Bart L. Scott, Nicolaus Kröger	15
10	P490: UPDATED SURVIVAL, BLOOD COUNT RECOVERY AND SAFETY RESULTS FROM THE AGILE STUDY IN PATIENTS WITH ACUTE MYELOID LEUKEMIA TREATED WITH IVOSIDENIB + AZACITIDINE COMPARED TO PLACEBO + AZACITIDINE 2023 ·HemaSphere ·Hartmut Döhner, Pau Montesinos, (unknown), Ewa Zarzycka, Jianxiang Wang, Marta Riva, Michael Heuser, Rodrigo T. Calado, Andre C. Schuh, Su‐Peng Yeh, Jianan Hui, Diego A. Gianolio, Prapti A. Patel, Christian Récher, Stéphane de Botton	0
11	Effective drug treatment identified by in vivo screening in a transplantable patient-derived xenograft model of chronic myelomonocytic leukemia 2020 ·Leukemia ·Arnold Kloos, (unknown), (unknown), Razif Gabdoulline, (unknown), Nidhi Jyotsana, (unknown), Renate Schottmann, Michaela Scherr, Charu Gupta, Felix F. Adams, Adrian Schwarzer, Dirk Heckl, Axel Schambach, Suzan Imren, R. Keith Humphries, Arnold Ganser, Felicitas Thol, Michael Heuser	9
12	IDH1/2 mutations in acute myeloid leukemia patients and risk of coronary artery disease and cardiac dysfunction—a retrospective propensity score analysis 2020 ·Leukemia ·Badder Kattih, (unknown), Piroska Klement, Abel Martin Garrido, Razif Gabdoulline, Alessandro Liebich, (unknown), Anuhar Chaturvedi, Timon Seeger, Felicitas Thol, Gudrun Göhring, Brigitte Schlegelberger, Robert Geffers, David John, Udo Bavendiek, Johann Bauersachs, Arnold Ganser, Joerg Heineke, Michael Heuser	37
13	Comprehensive clinical-molecular transplant scoring system for myelofibrosis undergoing stem cell transplantation 2019 ·Blood ·Nico Gagelmann, Markus Ditschkowski, (unknown), Swann Bredin, Marie Robin, Bruno Cassinat, Rabia Shahswar, Felicitas Thol, Michael Heuser, Gèrard Socié, Dietrich W. Beelen, Ioanna Triviai, Anita Badbaran, Nicolaus Kröger	107
14	Monocytes reprogrammed with lentiviral vectors co-expressing GM-CSF, IFN-α2 and antigens for personalized immune therapy of acute leukemia pre- or post-stem cell transplantation 2019 ·Cancer Immunology Immunotherapy ·(unknown), Michael Heuser, Arnold Ganser, Renata Stripecke	9
15	Preclinical Assessment of Suitable Natural Killer Cell Sources for Chimeric Antigen Receptor Natural Killer–Based “Off-the-Shelf” Acute Myeloid Leukemia Immunotherapies 2019 ·Human Gene Therapy ·Stephan Kloeß, Olaf Oberschmidt, (unknown), (unknown), (unknown), Arnold Kloos, Tanja Gardlowski, (unknown), Michael Heuser, Johann Meyer, Martin G. Sauer, Christine S. Falk, Ulrike Koehl, Axel Schambach, Michael Morgan	44
16	miR-625-3p is upregulated in CD8+ T cells during early immune reconstitution after allogeneic stem cell transplantation 2017 ·PLoS ONE ·Kriti Verma, Nidhi Jyotsana, (unknown), (unknown), Angelika Pfanne, Thomas Thum, Arnold Ganser, Michael Heuser, Eva M. Weissinger, Lothar Hambach	7
17	Synergistic Activity of IDH1 Inhibitor Bay-1436032 with Azacitidine in IDH1 Mutant Acute Myeloid Leukemia 2017 ·Blood ·Anuhar Chaturvedi, Charu Gupta, (unknown), Razif Gabdoulline, Stefan Kaulfuß, Kerstin Görlich, Renate Schottmann, Olaf Panknin, Markus Wagner, Robert Geffers, Arnold Ganser, Felicitas Thol, Michael Jeffers, Andrea Haegebarth, Michael Heuser	8
18	The E3 Ligase Itch Is a Regulator of Bone Marrow Mesenchymal Stem Cells and the Hematopoietic Stem Cell Niche 2017 ·Blood ·(unknown), Michael Heuser, Arnold Ganser, Chozha Vendan Rathinam	2
19	An optimized lentiviral vector system for conditional RNAi and efficient cloning of microRNA embedded short hairpin RNA libraries 2017 ·Biomaterials ·Felix F. Adams, Dirk Heckl, Thomas Hoffmann, Steven R. Talbot, Arnold Kloos, Felicitas Thol, Michael Heuser, Johannes Zuber, Axel Schambach, Adrian Schwarzer	15
20	Expression of Hedgehog Pathway Mediator GLI Represents a Negative Prognostic Marker in Human Acute Myeloid Leukemia and Its Inhibition Exerts Antileukemic Effects 2015 ·Clinical Cancer Research ·Jasmin Wellbrock, (unknown), Julian Köhler, Katharina Wagner, Hauke Stamm, Eik Vettorazzi, Gabi Vohwinkel, (unknown), (unknown), (unknown), Kristoffer Riecken, Sonja Loges, Felicitas Thol, Claudia Schubert, Michael Amling, Manfred Jücker, Carsten Bokemeyer, Michael Heuser, Jürgen Krauter, Walter Fiedler	86

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact